Interleukin-17A Inhibitor is Skuccizumab Injection.
Interleukin-17A is fully known as interleukin-17A inhibitor, also known as scuccizumab, is a biological agent, commonly used in the treatment of some autoimmune diseases, such as ankylosing spondylitis which is ineffective in conventional treatment, moderate to severe plaque psoriasis, etc. Biological agents have the advantages of fast onset of action, better efficacy, and good tolerability in the treatment of psoriasis.
Interleukin-17A inhibitors are prohibited for use in pregnant women, people with active infections, and should be used with caution in breastfeeding women, children, and people with hepatic or renal insufficiency, and common adverse reactions include upper respiratory tract infections, oral herpes, and tinea pedis.
The use of biologics such as interleukin-17A inhibitors must be evaluated by a medical professional and administered under medical supervision to avoid side effects and delays.